| ObjectiveThe purpose of this study was to investigate and evaluate the effect of oral nicergoline on improving cognitive function in patients with new cerebral infarction in a real medical environment.Randomly selected four groups of patients,within the scope of the safe dose given different doses of nicergolin,to observe the curative effect of the drug to improve cognitive function and safety,and through the follow-up rating,a conclusion clinical curative effect,supplementary nicergolin clinical drug information,and then provide more clinical experience for clinical drug use and safety,improve the quality of life of patients.MethodsThe inclusion criteria and exclusion criteria were formulated,and new cases of cerebral infarction admitted to the department of neurology,affiliated central hospital of Shenyang medical college from April 2017 to March 2018 were selected.192 patients were selected in strict accordance with the enrollment criteria and signed the informed consent for clinical efficacy observation.Patients with follow-up loss,self-withdrawal and adverse events were excluded,and a total of 173 patients met the requirements as the final study subjects.They were randomly divided into four groups:group A was given 5mg/time of nicergoline,group B was given 10mg/time of nicergoline,group C was given 15mg/time of nicergoline,and group D was given 20mg/time of nicergoline.Each group was given three times of nicergoline per day(once every 8 hours).Patients were followed up on the 30th,60th and 90th days after the drug administration,and the degree of improvement of clinical symptoms after the drug administration was inquired,and efficacy scores and comparative analysis were conducted.In this study,cognitive function and daily living ability were scored,and then statistical software was used to compare and analyze the scoring results,and finally the conclusion was drawn.Cognitive function and daily living ability were evaluated by three scoring scales,namely Montreal cognitive evaluation scale(MOCA),simple mental state testing scale(MMSE)and daily living ability scale(ADL).The higher the scores of Montreal cognitive assessment scale(MOCA)and simple mental state assessment scale(MMSE),the better the cognitive function.The daily living ability scale(ADL)assessed the patients' daily living ability,and the higher the score,the better the daily living ability.Accurately record the evaluation results,conduct data analysis,draw objective conclusions,summarize clinical medication experience.ResultsThe cognitive function and daily living ability of group A,B,C and D were evaluated at 30 days after taking the medicine compared with those before taking the medicine.There was no significant difference between group A(5mg/time)and group B(10mg/time)after 30 days of treatment(P>0.05).After 30 days of treatment,the MOCA scale and MMSE scale in group C(15mg/time)showed a P value equal to 0.051,which was close to the statistical significance of difference(P value 0.05),suggesting that there was a certain difference in clinical efficacy.After comparison of ADL scale scores in group C,no statistically significant difference was found(P>0.05).In group D,MOCA scale,MMSE scale and ADL scale were evaluated after 30 days of treatment,and the difference in score was statistically significant(P<0.05),suggesting that 20mg/time nicergoline had clear clinical efficacy after 30 days of treatment.MOCA scale,MMSE scale and ADL scale were evaluated 60 days after administration and without administration;The results of statistical analysis showed that the P value of group A(5mg/time)was>0.05,showing no significant statistical significance.The MOCA,MMSE and ADL scores of group B(10mg/time),group C(15mg/time)and group D(20mg/time)showed significant differences(P<0.05),among which the MOCA scales of group B showed smaller differences than those of MMSE and ADL scales.MOCA scale,MMSE scale and ADL scale in group C and group D showed significant differences(P<0.05);Comparison and analysis of MOCA scale,MMSE scale and ADL scale scores on the 90th day after administration of the four groups showed significant differences(P<0.05),which were statistically significant.Except that MOCA scale scores in group C were significantly different from those in group B,MMSE scale scores and ADL scale scores were not significantly different from those in group B.Compared with group B and group C,group D had no obvious advantage in the therapeutic effect.The above results suggest that the effect of clinical medication is time-dependent,and the longer the duration of medication,the better the effect.There is a dose-dependent relationship between the therapeutic effect and dose,but not all of the therapeutic effect is proportional to the dose-dependent relationship.After a certain dosage,there was no obvious dose-dependent relationship,suggesting the existence of maximum dosage.During the follow-up of group C and group D,it was found that some patients had dizziness,headache,nausea and other symptoms,and some patients had hot flashes and facial flushing,while group A and group B did not have the above symptoms.The analysis may be the adverse reactions of drugs,and the increase of drug adverse reactions after dosage increase is not excluded.ConclusionNicergoline is effective in the treatment of cognitive dysfunction after acute cerebral infarction.Significant therapeutic effects were observed at 90 days at 5mg/time,10mg/time,15mg/time and 20mg/time(three times of oral administration per day).There is a certain dose-dependent relationship between the therapeutic effects,but not all the therapeutic effects are proportional to the dose-dependent relationship.After reaching a certain dose-dependent relationship,there is no obvious dose-dependent relationship between the therapeutic effects,and the relative drug reactions can occur when the dose increases,suggesting the existence of the maximum dose-dependent.Clinical medication effect has a certain time dependence,the longer the medication duration,the better the effect. |
PDF Full Text Request